This is a prospective, observational, multi-center and a cohort study of biologic naïve patients with moderate to severe ulcerative colitis (UC) or Crohn’s disease (CD) who have had an inadequate response with, lost response to, or were intolerant to conventional therapy. This study will assess long-term clinical benefits in patients who are initiating treatment with vedolizumab. Patients that are initiated on treatment with vedolizumab will be recruited into cohorts of UC or CD. This study will enroll approximately 200 patients (100 patients with UC and 100 with CD) into 2 cohorts who have initiated a treatment with vedolizumab in a clinical practice. The study will be conducted at 23 sites in Greece. The data will be collected for up to 2 years or until discontinuation of vedolizumab treatment, whichever occurs earlier after enrolment in the study.
Trial at a glance
What medical condition is being studied? Inflammatory Bowel Disease
When is the trial being conducted?
From 18 Years
Accepts Healthy Volunteers?
Trial Details / Participation Requirements
CLICK TO EXPANDCLICK TO COLLAPSE
Trial Type: Observational